Literature DB >> 7524735

Detection of an L-selectin ligand on a hematopoietic progenitor cell line.

S M Oxley1, R Sackstein.   

Abstract

L-selectin, the peripheral lymph node "homing receptor," is an adhesion protein that mediates lymphocyte binding to lymph node high endothelial venules. Ligands for this protein have been identified only on endothelial cells, and recent murine studies indicate that CD34 on endothelial cells is an L-selectin ligand. To investigate whether CD34 expressed on hematopoietic cells functions as an L-selectin ligand, we used an in vitro binding assay to examine lymphocyte adherence to KG1a, a CD34+ human hematopoietic progenitor cell line. We observed specific L-selectin-mediated adherence of lymphocytes to KG1a: the binding was calcium-dependent, was strictly inhibited by anti-L-selectin antibodies and by carbohydrate ligands of L-selectin, and was abrogated by induction of L-selectin shedding from the lymphocyte membrane by treatment with phorbol esters. However, blocking studies using anti-CD34 antibodies, and experiments using KG1a cells sorted for CD34 expression and COS-7 cells transfected with full-length CD34 cDNA indicate that the ligand on KG1a is not CD34; moreover, RPMI 8402, a CD34+ cell line, does not support lymphocyte adherence in the binding assay. Treatment of KG1a with the enzymes neuraminidase, chymotrypsin, and bromelain abrogated lymphocyte binding to the cells, indicating that the ligand is a glycoprotein. These experiments show that CD34 on hematopoietic cells is not an L-selectin ligand and provide the first evidence of a ligand for L-selectin present on a non-endothelial cell.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524735

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells.

Authors:  C J Dimitroff; J Y Lee; R C Fuhlbrigge; R Sackstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Glycoengineering of HCELL, the human bone marrow homing receptor: sweetly programming cell migration.

Authors:  Robert Sackstein
Journal:  Ann Biomed Eng       Date:  2011-11-09       Impact factor: 3.934

Review 3.  Selectin-carbohydrate interactions during inflammation and metastasis.

Authors:  R P McEver
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 4.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 5.  Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration.

Authors:  Robert Sackstein
Journal:  Immunol Rev       Date:  2009-07       Impact factor: 12.988

Review 6.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

Review 7.  Fulfilling Koch's postulates in glycoscience: HCELL, GPS and translational glycobiology.

Authors:  Robert Sackstein
Journal:  Glycobiology       Date:  2016-02-29       Impact factor: 4.313

8.  The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion.

Authors:  L Healy; G May; K Gale; F Grosveld; M Greaves; T Enver
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

9.  Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen.

Authors:  Charles J Dimitroff; Thomas S Kupper; Robert Sackstein
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

10.  Sialylated, fucosylated ligands for L-selectin expressed on leukocytes mediate tethering and rolling adhesions in physiologic flow conditions.

Authors:  R C Fuhlbrigge; R Alon; K D Puri; J B Lowe; T A Springer
Journal:  J Cell Biol       Date:  1996-11       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.